News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
98,750 Results
Type
Article (11296)
Company Profile (24)
Press Release (87407)
Multimedia
Podcasts (92)
Webinars (12)
Section
Business (36532)
Career Advice (573)
Deals (6294)
Drug Delivery (108)
Drug Development (13424)
Employer Resources (44)
FDA (2101)
Job Trends (2402)
News (53151)
Policy (5077)
Tag
2027 BioCapital Standard (1)
2027 Genetown Standard (3)
2027 Pharm Country Standard (3)
Academia (212)
Accelerated approval (11)
ADA (14)
Adcomms (21)
Allergies (45)
Alliances (8654)
ALS (60)
Alzheimer's disease (365)
Antibody-drug conjugate (ADC) (142)
Approvals (2070)
Artificial intelligence (225)
ASCO (58)
Autoimmune disease (84)
Automation (10)
Bankruptcy (56)
Belgium (1)
Best Places to Work (1418)
BIO (21)
Biologics (4)
BIOSECURE Act (9)
Biosimilars (94)
BioSpace Insights (65)
Biotechnology (14)
Bispecific (2)
Bladder cancer (41)
Brain cancer (12)
Breast cancer (79)
Cancer (1112)
Cardiovascular disease (191)
Career advice (484)
Career pathing (31)
CAR-T (67)
CDC (14)
CDMO (85)
Celiac Disease (1)
Cell-line development (1)
Cell therapy (169)
Cervical cancer (5)
Clinical research (11704)
Collaboration (589)
Commercialization (6)
Company closure (3)
Compensation (126)
Complete response letters (39)
COVID-19 (485)
CRISPR (11)
C-suite (383)
Cystic fibrosis (19)
Data (1201)
Decentralized trials (1)
Denatured (15)
Depression (45)
Dermatology (42)
Diabetes (133)
Diagnostics (608)
Digital health (14)
Diversity (8)
Diversity, equity & inclusion (11)
Drug discovery (141)
Drug pricing (167)
Drug shortages (25)
Duchenne muscular dystrophy (92)
Earnings (10827)
Editorial (48)
Employer branding (6)
Employer resources (50)
Events (13573)
Executive appointments (301)
FDA (2693)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (405)
Gene editing (33)
Generative AI (39)
Gene therapy (154)
GLP-1 (510)
Government (897)
Grass and pollen (1)
Guidances (51)
Healthcare (1701)
Hematology (24)
HIV (19)
Huntington's disease (22)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (21)
Immunology and inflammation (172)
Immuno-oncology (45)
Indications (22)
Infectious disease (581)
Inflammatory bowel disease (41)
Inflation Reduction Act (7)
Influenza (30)
Intellectual property (48)
Interviews (80)
IPO (2260)
IRA (42)
Job creations (876)
Job search strategy (405)
JPM (40)
Kidney cancer (3)
Kidney disease (23)
Labor market (84)
Layoffs (247)
Leadership (34)
Legal (1168)
Licensing (11)
Liver cancer (20)
Longevity (8)
Lung cancer (166)
Lymphoma (97)
Machine learning (19)
Management (24)
Manufacturing (422)
Marketing (2)
MASH (59)
Medical device (554)
Medtech (563)
Mergers & acquisitions (4250)
Metabolic disorders (607)
mRNA (63)
Multiple sclerosis (45)
NASH (9)
Netherlands (2)
Neurodegenerative disease (114)
Neuropsychiatric disorders (52)
Neuroscience (827)
Neurotech (1)
NextGen: Class of 2026 (705)
Non-profit (196)
Now hiring (58)
Obesity (419)
Opinion (178)
Ovarian cancer (28)
Pain (75)
Pancreatic cancer (65)
Parkinson's disease (93)
Partnered (13)
Patents (140)
Patient recruitment (111)
Peanut (6)
People (11167)
Peptides (1)
Pharmaceutical (13)
Pharmacy benefit managers (22)
Phase 1 (3226)
Phase 2 (5281)
Phase 3 (4535)
Pipeline (1948)
Policy (198)
Postmarket research (309)
Preclinical (1132)
Press Release (5)
Prostate cancer (60)
Psychedelics (35)
Radiopharmaceuticals (94)
Rare diseases (317)
Real estate (1025)
Recruiting (22)
Regulatory (4313)
Reports (18)
Research institute (250)
Resumes & cover letters (102)
Rett syndrome (2)
RNA editing (11)
RSV (30)
Schizophrenia (74)
Series A (73)
Series B (46)
Service/supplier (2)
Sickle cell disease (19)
Special edition (24)
Spinal muscular atrophy (44)
Sponsored (9)
Startups (780)
Stomach cancer (10)
Substance use disorders (4)
Supply chain (57)
Tariffs (94)
The Weekly (75)
Vaccines (249)
Venture capital (95)
Weight loss (343)
Women's health (33)
Worklife (11)
Date
Last 7 days (102)
Last 30 days (417)
Last 365 days (5069)
2026 (3784)
2025 (5065)
2024 (5596)
2023 (6246)
2022 (8741)
2021 (8231)
2020 (7407)
2019 (5956)
2018 (4674)
2017 (6415)
2016 (5616)
2015 (5621)
2014 (3462)
2013 (2969)
2012 (3000)
2011 (2969)
2010 (2480)
Location
Africa (198)
Alabama (6)
Arizona (19)
Arkansas (1)
Asia (9868)
Australia (895)
California (1607)
Canada (673)
China (392)
Colorado (96)
Connecticut (125)
Delaware (51)
Europe (22380)
Florida (408)
Georgia (14)
Hawaii (1)
Idaho (5)
Illinois (135)
India (62)
Indiana (65)
Iowa (2)
Japan (237)
Kansas (48)
Kentucky (3)
Louisiana (3)
Maine (2)
Maryland (291)
Massachusetts (1313)
Michigan (29)
Minnesota (31)
Mississippi (2)
Missouri (6)
Montana (1)
Nebraska (4)
Nevada (10)
New Hampshire (3)
New Jersey (886)
New Mexico (16)
New York (433)
North Carolina (223)
Northern California (651)
Ohio (75)
Oklahoma (1)
Oregon (7)
Pennsylvania (440)
Puerto Rico (20)
Rhode Island (8)
South America (254)
South Carolina (3)
Southern California (794)
Tennessee (20)
Texas (155)
United States (6442)
Utah (22)
Virginia (27)
Washington D.C. (20)
Washington State (216)
West Virginia (1)
Wisconsin (16)
Wyoming (2)
98,750 Results for "horizon pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.
September 8, 2026
·
2 min read
·
Tristan Manalac
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
September 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Omnix Medical Launches New Horizon Europe PEPTAMR Infectious Disease Consortium
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections
July 13, 2026
·
1 min read
Job Trends
Pharmas face off for manufacturing talent amidst reshoring efforts
As pharmas reshore manufacturing, they’re squaring off with each other to find the right personnel to staff up their plants. That task is challenging given the limited talent pool, difficulty filling critical roles and, in some cases, competition from data centers.
September 23, 2026
·
5 min read
·
Angela Gabriel
Press Releases
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 6, 2026
·
8 min read
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.
June 26, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 6, 2026
·
5 min read
Press Releases
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
February 19, 2026
·
7 min read
China
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
When signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.
July 28, 2026
·
7 min read
·
Annalee Armstrong
Business
Deep dive: Pharma CEO compensation report
Who is the highest paid CEO in all of pharma? In this special edition,
BioSpace
examines top paid CEOs and their pay packages.
June 30, 2026
·
1 min read
·
Annalee Armstrong
1 of 9,875
Next
